Small Cap Stocks Are Heating up Again, Small Cap Street is Covering (OTCQB: ELTP),(OTCBB: AHIX), (OTCBB: AXXE), (OTCBB: CTIX)

NEW YORK, NY – January 26, 2016 -- InvestorsHub NewsWire -- Aluf Holdings, Inc. (OTCBB: AHIX) is a holding company that operates growth-oriented, proprietary software businesses. The companies they own, in whole or in part, are at various stages of development, ranging from established cash generating businesses to early stage development companies.
Over the past couple of months AHIX has completed joint venture and asset purchase agreements and folded them into a new operating entity called Aluf Biometrics, Inc. Get more details about AHIX and their recent acquisitions when you read the brief report at this link: http://bit.ly/1ZOqVe8

Axxess Pharma, Inc. (OTCBB: AXXE) operates through its Canadian Subsidiary: Axxess Pharma Canada Inc. AXXE is a specialty health care products company offering select medicines, all-natural nutritional supplements and over the counter remedies all across the Americas. Axxess Pharma holds the Tapout license to sell all-natural, globally branded nutraceutical products, including pain relief sprays and wipes.
AXXE share have shown some traction lately after the company announced some positive events in December regarding manufacturing and sales. We have more information on these developments in the brief report at this link: http://bit.ly/1ZOqVe8
Cellceutix Corp. (OTCBB: CTIX) is a clinical stage biopharmaceutical company developing therapies in multiple diseases. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center.
Last week the company received a letter from the U.S. Food and Drug Administration granting Orphan Drug Designation to Kevetrin for the treatment of pancreatic cancer. Get more information about Kevetrin and its potential in the brief report you can read here: http://bit.ly/1ZOqVe8

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.
The FDA just granted ELTP a waiver of the application fee ($2,335,200) required for the filing of a New Drug Application. Find out how the FDA waiver affects the company a get a review of their product technology in the brief report you can read here: http://bit.ly/1ZOqVe8

FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapstreet.com. For any urgent concerns or inquiries please contact us at editor@smallcapstreet.com.

About Small Cap Street

We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below.

Contact: editor@Smallcapstreet.com

SOURCE: Small Cap Street